

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

13th April, 2016

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 13 of the Listing Regulations - Statement of Investor complaints

Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the Statement of Investor Complaints for the quarter ended on 31st March, 2016 as under:

#	Details of Investor Complaints	Number of Complaints
1.	Pending at the beginning of the quarter as on 01.01.2016	0
2.	Received during the quarter ended 31.03.2016	7
3.	Disposed off during the quarter ended 31.03.2016	7
4.	Remaining Unresolved at the end of the quarter ended 31.03.2016	0

Kindly acknowledge receipt.

Thanking You,

Yours faithfully, for AJANTA PHARMA LIMITED

GAURANG SHAH Sr. G.M. - Legal & Company Secretary